- Home
- HCWB
HCWB
HCW Biologics Inc.
as 11-14-2024 3:33pm EST
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Upcoming Earnings Alert:
Get ready for potential market movements as HCW Biologics Inc. HCWB prepares to release earnings report on 19 Nov 2024.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | MIRAMAR |
| Market Cap: | 26.6M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 96.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.28 - $1.93 | Next Earning Date: | 11-19-2024 |
| Revenue: | $3,922,670 | Revenue Growth: | 2.82% |
| Revenue Growth (this year): | -59.53% | Revenue Growth (next year): | N/A |
Latest HCW Biologics Inc. News
HCWB Breaking Stock News: Dive into HCWB Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 months ago
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
Simply Wall St.
3 months ago
Bullish HCW Biologics Insider Buying Worth US$2.57m Yet To Pay Off
GlobeNewswire
3 months ago
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
6 months ago
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
7 months ago
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights
Simply Wall St.
9 months ago
Rebecca Byam Bought 122% More Shares In HCW Biologics
Market Exclusive
10 months ago
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
GlobeNewswire
10 months ago
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
Compare HCWB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HCWB HCW Biologics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.